A Phase 2 interventional study of Amlitelimab and Placebo in Hidradenitis, sponsored by Sanofi. Terminated at 42 sites in 11 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hidradenitis with a site in United States — 6 open to participants now, 10 under way, 5 of them phase 3. Hidradenitis · United States.
Among the 25 studies in Hidradenitis with a site in United States, this one is the 15th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 in phase 2, and was the 11th registered.
34 studies on the registry are indexed under Hidradenitis; 9 are open to participants now.
Browse Hidradenitis studies →6 of the 25 studies in Hidradenitis with a site in United States are open now. Recruiting first, the newest first:
Sanofi · Sites in United States, Canada
Ages 18+
Spyre Therapeutics, Inc. · Sites in United States, Canada
Ages 18–75
Incyte Corporation · Sites in United States, Canada
Ages 12–17
Incyte Corporation · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Wayne State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Hidradenitis studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 10
First in 2011; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is below the median of 121 across 28 interventional studies indexed under Hidradenitis.
Median enrollment 153 across the 24 interventional studies, 743 across the 1 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 25 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 3 studies filed under Hidradenitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Hidradenitis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT07766005Spyre Therapeutics, Inc.A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Hidradenitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a parallel, Phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (PK), and biological effects of treatment of subcutaneous injection of amlitelimab compared with placebo in male and female participants aged 18 to 70 years with moderate to severe hidradenitis suppurativa (HS).
The purpose of this study is to measure standardized clinician reported and participant-reported outcomes (ClinRO and PRO), safety, and drug concentration. An optional long-term extension (LTE) period will assess chronic safety and efficacy over an additional 80 weeks of amlitelimab treatment.
Study details include:
The study duration per participant will be up to 116 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection (SC) as per protocol.
Drug: Amlitelimab
Subcutaneous injection as per protocol.
Drug: Placebo
Injection solution SC injection
Also known as: SAR445229
Injection solution SC injection
The clinical response as measured by the percentage of participants achieving HiSCR50 at Week 16
Hidradenitis suppurativa clinical response (HiSCR)50 is defined as ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.
Time frame: Week 16
Time to onset of achieving HiSCR50
HiSCR50 is defined as ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.
Time frame: From baseline to Week 16
Absolute change from baseline in AN count at Week 16
AN count is the total abscess and inflammatory nodule count.
Time frame: Baseline to Week 16
Percentage change in AN count at Week 16
AN count is the total abscess and inflammatory nodule count.
Time frame: Baseline to Week 16
Percentage of participants achieving HiSCR75 at Week 16
HiSCR75 is defined as ≥75% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.
Time frame: Week 16
Percentage of participants achieving HiSCR90 at Week 16
HiSCR90 is defined as ≥90% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.
Time frame: Week 16
Percentage of participants who experience improvement by at least 1 International Hidradenitis Suppurativa Severity Score System (IHS4) stage at Week 16
The IHS4 is a validated tool to assess HS severity. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.
Time frame: Week 16
Change in absolute score from Baseline in IHS4 at Week 16
The IHS4 is a validated tool to assess HS severity. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.
Time frame: Baseline to Week 16
Percentage of participants who experience a flare at Week 16
A flare is defined as at least a 25% increase in AN count (with a minimum increase of 2 AN) relative to baseline. AN count is the total abscess and inflammatory nodule count.
Time frame: Week 16
Percentage of participants achieving IHS4-55 at Week 16
IHS4-55 is defined as achievement of a 55% reduction in IHS4 score from baseline. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.
Time frame: Week 16
Percentage of participants achieving at least 30% reduction and at least 1 unit reduction from Baseline in weekly average of daily HS-Skin Pain NRS at Week 16 among participants with baseline NRS ≥3
Hidradenitis Suppurativa-Skin pain-numeric rating scale (HS-Skin pain NRS) is scored on a 0 to 10 scale with 0 indicating "no skin pain" and 10 indicating "worst skin pain possible".
Time frame: Week 16
Percentage of participants with improvement (reduction) in Peak Pruritus Numerical Rating Scale (PP-NRS) ≥4 from Baseline at Week 16 among participants with baseline PP-NRS ≥4
PP-NRS is a validated single item 0 (no itch) to10 (worst itch imaginable) numeric rating scale assessing peak pruritus (itch).
Time frame: Week 16
Percentage of participants who experience 5-point reduction in DLQI at Week 16 among participants with baseline DLQI ≥4
Dermatology life quality index (DLQI) is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL). Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Time frame: Week 16
Change from Baseline in the total Hidradenitis Suppurativa Quality of Life (HiSQOL) score at Week 16
HiSQOL is an instrument designed to measure the HS-specific health-related QoL of adults with HS.
Time frame: Baseline to Week 16
Incidence of treatment-emergent adverse events (TEAEs), adverse event of special interest (AESIs), and serious adverse events (SAEs) including local injection site reactions in the Safety Population
Time frame: Baseline up to Week 116
Incidence of potentially clinically significant abnormalities in laboratory tests, vital signs, and electrocardiograms in the Safety Population
Time frame: Baseline up to Week 116
Serum amlitelimab concentrations measured at prespecified time points in the PK population
Time frame: Day 1 up to Week 116
Incidence of antidrug antibodies (ADA) of amlitelimab at prespecified timepoints in the ADA population
Time frame: Day 1 up to Week 116
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Nov 2023 to primary completion in Feb 2025, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlitelimab